Back to funds
View filing
Aisling Capital Management LP
hedge fundUpdated 28 days agoManaged by Aisling Capital Management Lp • Latest filing Q2 2026
Portfolio value
$471.6M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
35.5%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $207.8M |
| Q2 2023 | $204.1M |
| Q3 2023 | $242.7M |
| Q4 2023 | $335.2M |
| Q1 2024 | $295.5M |
| Q2 2024 | $231.1M |
| Q3 2024 | $261.1M |
| Q4 2024 | $281.8M |
| Q1 2025 | $288.5M |
| Q2 2025 | $359.7M |
| Q3 2025 | $456.4M |
| Q4 2025 | $478.9M |
| Q1 2026 | $476.3M |
| Q2 2026 | $471.6M |
Top holdings
14 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | B BBIO BRIDGEBIO PHARMA INC | $341.8M | 4.59M | 72.48% | — |
| 2 | M MNST MONTE ROSA THERAPEUTICS INC | $37.6M | 1.56M | 7.98% | — |
| 3 | S SNDX SYNDAX PHARMACEUTICALS INC | $28.8M | 1.32M | 6.10% | — |
| 4 | C CMPS COMPASS PATHWAYS PLC | $20.3M | 1.43M | 4.30% | — |
| 5 | B BCAX BICARA THERAPEUTICS INC | $16.9M | 568.9K | 3.58% | — |
| 6 | ? N/A BRIDGEBIO ONCOLOGY THERAPEUT | $7.8M | 1.02M | 1.64% | — |
| 7 | S SRRK SCHOLAR ROCK HLDG CORP | $4.2M | 77.0K | 0.90% | — |
| 8 | U URGN UROGEN PHARMA LTD | $4M | 108.0K | 0.84% | — |
| 9 | ? N/A BIOMEA FUSION INC | $3M | 2.05M | 0.64% | — |
| 10 | A ACRS ACLARIS THERAPEUTICS INC | $2.3M | 434.5K | 0.49% | — |
| 11 | E EPRX EUPRAXIA PHARMACEUTICALS INC | $2.1M | 325.0K | 0.46% | — |
| 12 | V VTVT VTV THERAPEUTICS INC | $1.9M | 50.0K | 0.40% | — |
| 13 | M MRKR MARKER THERAPEUTICS INC | $478K | 325.4K | 0.10% | — |
| 14 | O OKUR ONKURE THERAPEUTICS INC | $404K | 88.6K | 0.09% | — |